CluenexViatris VTRS
Viatris scores weak on business quality (2.8 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Viatris does
Viatris develops and sells generic and branded pharmaceutical drugs globally, generating revenue by supplying pharmacies, hospitals, and distributors with essential medicines. The business is navigating a multi-year restructuring phase to stabilize its product portfolio and reduce leverage.
- What it does best
Viatris excels at global manufacturing scale in generic pharmaceuticals, generating $1.8B in free cash flow despite contracting top-line trends. This manufacturing footprint enables broad distribution that smaller generic competitors struggle to replicate efficiently.
- The main risk
Heavy debt burdens remain a central vulnerability, with total debt at $14.4B overshadowing cash reserves and constraining operational flexibility. High leverage leaves little room for execution missteps as revenue continues to drift downward.
Quality, check by check
Scored against its own industry, from company filings.
Operating margins of 8.2% and negative net margins reflect ongoing cost pressures. Profitability remains constrained by heavy debt servicing and declining revenue scale.
Scale acts as the primary moat, locking in global distributors through vast product breadth. However, a gross margin sector percentile of 22nd limits pricing power against nimble competitors.
Revenue is shrinking at a 3.0% annual rate, marking a continuation of declines seen across recent history annual summaries. The core engine is contracting rather than accelerating.
Interest coverage sits at 2.5x, leaving debt servicing tightly coupled to cash generation. Free cash flow of $1.8B provides cash, but net debt of $13.0B shows financial conditions remain heavy.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on VTRS
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Viatris scores weak on the Cluenex quality check (2.8 of 10), measured against its own industry. Profitability is weak, moat weak, growth slow and financial health weak.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Nov 5, 2026.
See VTRS today
- Today's verdict on VTRS, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Viatris (VTRS)”, https://cluenex.com/stocks/vtrs/, data as of Oct 10, 2026.